How to Invest in Neuralink Pre-IPO

How to Invest in Neuralink Pre-IPO

Neuralink is one of the most widely misreported valuations in private markets, so it is worth establishing the numbers precisely before looking at how to take exposure.

The valuation, precisely

Neuralink's last confirmed priced round was a $650 million Series E at $50.50 per share, closed 2 June 2025, at a $9.65 billion post-money valuation. Total capital raised across the company's life is about $1.34 billion. As of mid-August 2026, secondary-market records still list that June 2025 round as the most recent priced financing.

You will also have seen "Neuralink valued at $42 billion." That figure comes from secondary-market transaction data, reported in July 2026, showing shares changing hands between roughly $29 billion and $42 billion in implied valuation, with bids reported as high as $60 billion. Those are trading prints, not a funding round. A print tells you what one buyer paid one seller on one day. A priced round tells you what a lead investor and a company agreed after diligence. Keeping the two apart is what lets you read this market accurately.

A reported May 2026 investment by a sovereign wealth fund at an undisclosed valuation circulates widely but could not be corroborated against a primary source. Claims of specific implant counts in 2026 appear largely on low-quality aggregator sites. Treat all of it as unverified.

What is documented: Neuralink received FDA Breakthrough Device Designation for severe speech impairment, and Reuters has reported trial enrolment expanding to 21 participants worldwide with no serious device-related adverse events — though the dating of that report is itself inconsistent across syndications.

The company has no revenue and no IPO filing or timeline.

Why the gap between the round and the prints is so wide

A three-to-four-times spread between a priced round and secondary prints is unusual, and there are structural reasons for it here.

Neuralink is a scarcity asset. Very little stock is available, the company raises infrequently, and demand is driven by a theme — brain-computer interfaces — with no listed comparable. When supply is tiny and interest is broad, prints detach from fundamentals. That is a description of the market microstructure, not an argument that the price is right or wrong.

The June 2026 SpaceX listing intensified this. A successful public debut for one Musk-associated company pulled attention toward the others, and secondary pricing across that cluster moved on sentiment rather than on new information about the companies themselves.

For an investor, the useful implication is this: scarcity itself is part of what sets the price here, alongside the underlying technology story. Knowing which of the two you are responding to is what makes the position a considered one.

Why this exposure has been hard to reach

Neuralink is among the hardest names in this category to reach conventionally, and the reason is arithmetic.

The float is small. The company raises infrequently and has raised about $1.34 billion in total across its life. Conventional access requires accredited-investor status and tickets commonly starting around $100,000, against a limited supply of available stock, with wide spreads between indicative and executable pricing. Transfers need company consent, settlement takes weeks, and with no filing there is no exit date to work toward.

That is a six-figure commitment at a negotiated price, with no defined route out — which is exactly the gap tokenized exposure closes.

How OpenStocks gives you Neuralink exposure

Neuralink is one of four products live in the OpenStocks app, as oNEURALINK, a source-verified BEP-20 token on BNB Chain providing tokenized price exposure to Neuralink. For how these instruments are constructed and verified, start with what tokenized pre-IPO stocks are.

OpenStocks issues the token rather than operating the market: the Trade action routes to PancakeSwap, 0x, 1inch, ParaSwap or an in-wallet swap on Bitget, Binance, OKX or Gate, funded with USDT on BNB Chain, and the displayed price is the live USDT-quoted price from PancakeSwap Infinity.

Eligibility is a threshold question here as everywhere: OpenStocks is not available in the United States, to U.S. persons, or to other ineligible individuals.

The product page is genuinely useful for a company that reports infrequently, because it publishes the two things a private quote never separates:

• Implied valuation from the token price, and mark valuation from the reference price

• Premium % — the gap between them

On a scarcity asset, that premium field is genuinely useful. A negative premium means the token is trading below its reference mark; a positive premium means the opposite. Either way you can see exactly where the traded price sits — which is precisely what you cannot do when negotiating a private block. Alongside those, the page shows 30-day change, 24-hour volume, pool liquidity, 24-hour trade count and the contract address on BscScan — so the reference mark, the traded price and the gap between them are all visible in one place. Audit reports are published in the OpenStocks Security Center — including an independent smart-contract audit by QuillAudits — with all high findings listed as resolved.

Against the barrier list above: exposure is fractional rather than gated behind a six-figure ticket, it is not locked until an exit that has no date, and every input you would use to size a position is published and verifiable on-chain.

How to hold a scarcity asset well

Neuralink rewards precision more than most positions, and the tools for that are all on the page.

Anchor to the confirmed round. The $9.65 billion June 2025 valuation is the priced reference. Secondary prints tell you what buyers have paid since; both are useful, and they are different numbers.

Use the premium as your gauge. Because OpenStocks publishes token price against mark price, you can always see where the traded price sits relative to the reference rather than inferring it.

Watch the regulatory milestones. The FDA Breakthrough Device Designation for severe speech impairment and the expansion of trial enrolment are the developments that move the underlying story, and the product page carries a curated news feed for exactly this.

Size it as a long-horizon position. With no filing and no announced timeline, this is exposure to a technology thesis rather than a dated event.

For a hard-technology name with contracted revenue and federal programs, compare Anduril. For the broader lessons on product structure from 2026, see what the SpaceX IPO taught private-market investors.

FAQ

What is Neuralink's valuation?

The last confirmed priced round was $9.65 billion post-money, June 2025. Secondary prints in 2026 have implied $29–42 billion, with bids reported to $60 billion. Those prints are not a funding round.

Is Neuralink going public?

No filing, no timeline.

Does Neuralink have revenue?

No.

Can I buy Neuralink shares as a retail investor?

Not the shares. Direct secondaries require accreditation and large minimums; fractional tokenized exposure is available to eligible non-U.S. users.